Navigating the Arena: Platform Trials

In this episode of "In the Interim…", Dr. Scott Berry delivers a metaphoric critique of single-question trial infrastructure through the sports arena analogy, illustrating the cost, patient burden, and data inefficiency of conventional clinical trials. He provides a methodical comparison of traditional trial models and the platform trial approach, clarifying distinctions between platform, basket, and master protocol structures. Through examples from HEALEY ALS, I-SPY 2, PALM (Ebola), REMAP-CAP, RECOVERY, EPAD, GBM AGILE, and Precision Promise, Scott outlines the measurable efficiencies of platform trials: shared control arms, flexible arm addition and removal, reduced placebo exposure, accelerated timelines, and improved statistical inferences. The episode further examines platform trial performance during the COVID-19 pandemic, highlighting  trial adaptability, and the rapid generation of actionable evidence. Scott also addresses failure scenarios, focusing on EPAD Alzheimer’s as a cautionary case in platform sustainability, cost allocation, and initial funding barriers. Listeners will gain a perspective on the operational and statistical design choices governing today’s most innovative clinical studies.

Key Highlights

• Arena analogy applied to delineate clinical research inefficiency.
• Operational, statistical, and patient-focused efficiencies in platform versus single-question trials.
• Precision in terminology: platform, basket, and master protocol definitions.
• Effects of platform trials on speed and scientific rigor.
• Factors underlying both platform trial successes and failures.

For more, visit us at https://www.berryconsultants.com/